Regeneron Pharmaceuticals (NASDAQ:REGN) announced positive early-stage data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
REGN1979 is an investigational bispecific monoclonal antibody and is designed to trigger tumor killing by binding to both a B-cell tumor protein and an immune system T-cell receptor.
The company says the emerging data, which includes patients with R/R diffuse large B-cell lymphoma who had progressed after CAR-T therapy, will be presented at the European Hematology Association meeting.
REGN +0.19% after hours to $308.00.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.